16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer.

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Metabolic reprogramming is a hallmark of cellular transformation, yet little is known about metabolic changes that accompany tumor metastasis. Here we show that primary breast cancer cells display extensive metabolic heterogeneity and engage distinct metabolic programs depending on their site of metastasis. Liver-metastatic breast cancer cells exhibit a unique metabolic program compared to bone- or lung-metastatic cells, characterized by increased conversion of glucose-derived pyruvate into lactate and a concomitant reduction in mitochondrial metabolism. Liver-metastatic cells displayed increased HIF-1α activity and expression of the HIF-1α target Pyruvate dehydrogenase kinase-1 (PDK1). Silencing HIF-1α reversed the glycolytic phenotype of liver-metastatic cells, while PDK1 was specifically required for metabolic adaptation to nutrient limitation and hypoxia. Finally, we demonstrate that PDK1 is required for efficient liver metastasis, and its expression is elevated in liver metastases from breast cancer patients. Our data implicate PDK1 as a key regulator of metabolism and metastatic potential in breast cancer.

          Related collections

          Author and article information

          Journal
          Cell Metab.
          Cell metabolism
          1932-7420
          1550-4131
          Oct 6 2015
          : 22
          : 4
          Affiliations
          [1 ] Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada; Department of Biochemistry, McGill University, Montréal, QC H3A 1A3, Canada.
          [2 ] Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada; Department of Medicine, McGill University, Montréal, QC H3A 1A3, Canada.
          [3 ] Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada; Department of Physiology, McGill University, Montréal, QC H3A 1A3, Canada.
          [4 ] Department of Pathology, McGill University Health Center, Montréal, QC H4A 3J1, Canada.
          [5 ] Genetic Pathology Evaluation Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6H 3Z6, Canada.
          [6 ] Department of Medicine, University of Toronto, Toronto, ON M5G 2M9, Canada.
          [7 ] Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.
          [8 ] Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, Montréal, QC H3T 1E2, Canada.
          [9 ] Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada; Department of Physiology, McGill University, Montréal, QC H3A 1A3, Canada. Electronic address: russell.jones@mcgill.ca.
          [10 ] Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada; Department of Biochemistry, McGill University, Montréal, QC H3A 1A3, Canada; Department of Medicine, McGill University, Montréal, QC H3A 1A3, Canada. Electronic address: peter.siegel@mcgill.ca.
          Article
          S1550-4131(15)00398-8
          10.1016/j.cmet.2015.08.007
          26365179
          4acb24cb-fdc2-4463-8260-2e8e8bb7cf14
          Copyright © 2015 Elsevier Inc. All rights reserved.
          History

          Comments

          Comment on this article